LBI-HTA - Publications - Search - Year: 2014
Number of items: 25.

Fischer, S. and Zechmeister-Koss, I. (2014): Vasoprotectives: Efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoidal diseases. HTA-Projektbericht 79.

Nachtnebel, A. (2014): Horizon Scanning in Oncology: Results of the 21st Prioritisation – 4th quarter 2014. HSO: 21st Prioritisation.

Kisser, A. and Mayer, J. and Wild, C. (2014): Opportunities and strategies to drive appropriate use of MRI in Austria. HTA-Projektbericht 80.

Breuer, J. and Reinsperger, I. and Piso, B. (2014): Acupuncture - areas of application, current evidence and proven indications. HTA-Projektbericht 78.

Kisser, A. and Zechmeister-Koss, I. (2014): Procedural guidance for the systematic evaluation of biomarker tests. Decision Support Document 77.

Rothschedl, E. and Joppi, R. and Poggiani, C. (2014): Idelalisib (Zydelig®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 49.

Reinsperger, I. and Piso, B. (2014): Re-orientation of the Austrian parent-child preventive care programme, part X: further development of the mother-child-pass.. Decision Support Document 78.

Patera, N. and Wild, C. (2014): Assessment – APPRAISAL – Decision: (Good) Practice examples and recommendations. Decision Support Document 72.

Fischer, S. and Zechmeister-Koss, I. (2014): Costs of day surgery in Austria: An analysis of data and methods for varicose vein surgery as an example. HTA-Projektbericht 71.

Nachtnebel, A. and Breuer, J. (2014): Ibrutinib (Imbruvica®) for relapsed or refractory chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 47.

Hepperger, C. and Nachtnebel, A. (2014): Bevacizumab (Avastin®) for platinum-resistant recurrent, epithelial ovarian, fallopian tube or primary peritoneal cancer. DSD: Horizon Scanning in Oncology 48.

Breuer, J. and Nachtnebel, A. (2014): Horizon Scanning in Oncology: Results of the 20th Prioritisation – 3rd quarter 2014. HSO: 20th Prioritisation.

Rothschedl, E. and Nachtnebel, A. (2014): Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal carcinoma. DSD: Horizon Scanning in Oncology 46.

Breuer, J. and Nachtnebel, A. (2014): Horizon Scanning in Oncology: Results of the 19th Prioritisation – 2nd quarter 2014. HSO: 19th Prioritisation.

Piso, B. and Reinsperger, I. (2014): Sustainability of inpatient psychiatric rehabilitation for adults: systematic review. HTA-Projektbericht 75.

Breuer, J. and Nachtnebel, A. (2014): Horizon Scanning in Oncology: Results of the 18th Prioritisation – 1st quarter 2014. HSO: 18th Prioritisation.

Breuer, J. and Joppi, R. and Poggiani, C. and Dabrowska, M. and Zawodnik, A. and Nachtnebel, A. (2014): Obinutuzumab (Gazyva®) for previously untreated patients with chronic lymphocytic leukaemia (CLL). DSD: Horizon Scanning in Oncology 45.

Kisser, A. and Kirisits, A. (2014): Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of peritoneal carcinomatosis . Decision Support Document 74.

Breuer, J. and Joppi, R. and Poggiani, C. and Polkowska, M. and Nachtnebel, A. (2014): Radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. DSD: Horizon Scanning in Oncology 44.

Zechmeister-Koss, I and Fischer, S. (2014): Drug eluting stents for the treatment of peripheral artery disease. Decision Support Document 75.

Wild, C. and Patera, N. (2014): Stereotactic Radiofrequency ablation/ SRFA for hepatocellular carcinoma and liver metastases. Decision Support Document 76.

Breuer, J. and Nachtnebel, A. (2014): Implantation of endobronchial valves in patients with emphysema. Decision Support Document 20/ Update 2014.

Reinsperger, I. and Nachtnebel, A. (2014): Percutaneous left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation (1st Update 2014). Decision Support Document 44/ Update 2014.

Semlitsch, T. and Zengerer, A. and Jeitler, K. (2014): Nab-Paclitaxel (Abraxane®) as first-line therapy for metastatic adenocarcinoma of the pancreas. DSD: Horizon Scanning in Oncology 43.

Wild, C. and Blagojevic, S. (2014): Annual Report 2013.

This list was generated on Tue Apr 25 22:00:04 2017 CEST.